Moreover, EZH2 inhibition substantially increased the intratumoral trafficking of activated CD8+ and CD4+ T cells (decreasing the relative number of regulatory T cells, Tregs) and increased M1 tumor-associated macrophages (TAMs) (decreasing the tumor-promoting M2 macrophages). Here, CD8A is linked to neoplasm.